Macular retinal capillary hemodynamics in diabetic patients ,
, Ophthalmology, vol.98, issue.10, pp.1580-1586, 1991.
Non-retinovascular leakage in diabetic maculopathy, Br J Ophthalmol. août, vol.79, issue.8, pp.728-759, 1995. ,
Intrachoroidal microvascular abnormality: a previously unrecognized form of choroidal neovascularization, Am J Ophthalmol, vol.124, issue.4, pp.473-87, 1997. ,
Müller cells in the healthy and diseased retina, Prog Retin Eye Res. juill, vol.25, issue.4, pp.397-424, 2006. ,
Expression of aquaporins in the retina of diabetic rats, Curr Eye Res. sept, vol.36, issue.9, pp.850-856, 2011. ,
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care, janv, vol.37, issue.1, pp.9-16, 2014. ,
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial, Arch Ophthalmol Chic Ill, vol.126, issue.12, pp.1707-1722, 1960. ,
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus, Cochrane Database Syst Rev. 14 févr, issue.2, p.9122, 2014. ,
Global prevalence and major risk factors of diabetic retinopathy, Diabetes Care. mars, vol.35, issue.3, pp.556-64, 2012. ,
OEdèmes maculaires -Rapport SFO, vol.676, 2016. ,
, Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group, Arch Ophthalmol Chic Ill, vol.103, issue.12, pp.1796-806, 1960.
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science. 25 févr, vol.219, issue.4587, pp.983-988, 1983. ,
Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis, J Clin Invest, vol.84, issue.5, pp.1470-1478, 1989. ,
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells, Biochem Biophys Res Commun. 15 juin, vol.161, issue.2, pp.851-859, 1989. ,
Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema, Ophthalmology. sept, vol.110, issue.9, pp.1690-1696, 2003. ,
Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors, J Biol Chem. 13 août, vol.274, issue.33, pp.23463-23470, 1999. ,
Modulation of VEGFinduced retinal vascular permeability by peroxisome proliferator-activated receptor?/?. Invest Ophthalmol Vis Sci, vol.55, pp.8232-8272, 2014. ,
Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data, Am J Ophthalmol. déc, vol.172, pp.72-81, 2016. ,
Diabetic retinopathy: more than meets the eye, Surv Ophthalmol. déc, vol.47, issue.2, pp.253-262, 2002. ,
Triamcinolone acetonide destabilizes VEGF mRNA in Müller cells under continuous cobalt stimulation, Invest Ophthalmol Vis Sci, vol.46, issue.11, pp.4336-4377, 2005. ,
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant, Invest Ophthalmol Vis Sci. 5 janv, vol.52, issue.1, pp.80-86, 2011. ,
Accidental injection of dexamethasone intravitreal implant in the crystalline lens, Acta Ophthalmol (Copenh). juin, vol.92, issue.4, pp.330-331, 2014. ,
Accidental injections of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens, Eur J Ophthalmol. août, vol.24, issue.4, pp.633-639, 2014. ,
Inadvertent dexamethasone implant injection into the lens body management, Eur J Ophthalmol. août, vol.24, issue.4, pp.620-622, 2014. ,
Desegmentation of Ozurdex implant in vitreous cavity: report of two cases, Br J Ophthalmol. juill, vol.98, issue.7, pp.961-964, 2014. ,
Fractured Ozurdex TM implant in the vitreous cavity, Indian J Ophthalmol. juill, vol.60, issue.4, pp.337-345, 2012. ,
Split Ozurdex implant: a caution, Can J Ophthalmol J Can Ophtalmol. févr, vol.48, issue.1, pp.15-16, 2013. ,
Splitting of a Dexamethasone Implant (Ozurdex) following the Injection, Case Rep Ophthalmol Med, p.247949, 2013. ,
INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY, Retina Phila Pa. juin, vol.36, issue.6, pp.1143-52, 2016. ,
Micro-implant d'acétonide de fluocinolone (ILUVIEN®) pour l'oedème maculaire diabétique chronique, J Fr Ophtalmol. févr, vol.38, issue.2, pp.159-67, 2015. ,
Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema, Ophthalmology. mai, vol.116, issue.5, pp.914-934, 2009. ,
Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema, Acta Diabetol. août, vol.55, issue.8, pp.789-96, 2018. ,
Defining response to anti-VEGF therapies in neovascular AMD, Eye Lond Engl. juin, vol.29, issue.6, pp.721-752, 2015. ,
OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study, Retina Phila Pa. juin, vol.38, issue.6, pp.1110-1119, 2018. ,
Analysis of anatomical biomarkers in subtypes of diabetic macular edema refractory to anti-vascular endothelial growth factor treated with dexamethasone implant, Eur J Ophthalmol. 4 mars, p.1120672119834182, 2019. ,
Association of Disorganization of Retinal Inner Layers With Vision After Resolution of Center-Involved Diabetic Macular Edema, JAMA Ophthalmol. juill, vol.133, issue.7, pp.820-825, 2015. ,
Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers ,
, Acta Ophthalmol (Copenh). juin, vol.97, issue.4, pp.540-544, 2019.
OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant, Ophthalmology, vol.125, issue.2, pp.267-75, 2018. ,
Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema, Am J Ophthalmol. janv, vol.159, issue.1, pp.1-3, 2015. ,
Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers ,
, Acta Ophthalmol (Copenh). juin, vol.97, issue.4, pp.540-544, 2019.
, Retina Phila Pa. déc, vol.36, issue.12, pp.2319-2347, 2016.
Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema, Br J Ophthalmol, vol.102, issue.2, pp.195-203, 2018. ,
Diabetic macular oedema, Lancet Diabetes Endocrinol, vol.5, issue.2, pp.143-55, 2017. ,
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema, Ophthalmology. avr, vol.118, issue.4, pp.615-640, 2011. ,
Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies, Ophthalmol Retina. août, vol.3, issue.8, pp.663-672, 2019. ,
Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory, J Diabetes Res, p.2156273, 2016. ,
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema, Ophthalmology. oct, vol.121, issue.10, pp.1904-1918, 2014. ,
Early versus late switch: How long should we extend the anti-vascular endothelial growth factor therapy in unresponsive diabetic macular edema patients?, Eur J Ophthalmol. 16 mai, 2019. ,
Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response, Ophthalmology, vol.123, issue.11, pp.2368-75, 2016. ,
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema, Ophthalmology. déc, vol.118, issue.12, pp.5-14, 2011. ,
DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study, Retina Phila Pa. janv, vol.39, issue.1, pp.44-51, 2019. ,
,
, J Fr Ophtalmol. juin, vol.37, issue.6, pp.480-485, 2014.
, Résumé Introduction : L'oedème maculaire diabétique (OMD) est une cause majeure de baisse de l'acuité visuelle dans les pays développé. Plusieurs molécules sont disponibles : les anti-VEGFs en première intention, et l'implant intravitréen (Ozurdex®) de dexaméthasone en seconde
existe-t-il des critères incitant à un switch précoce vers l'Ozurdex® plutôt qu'à un maintien sous anti-VEGF ? ,
Analyse rétrospective observationnelle de tous les oedème maculaire diabétique résistants aux anti-VEGFs ayant bénéficié d'injection(s) d'Ozurdex® avec suivi sur 6 mois ,
, Résultats : 32 yeux ont été inclus. A 6 mois, nous retrouvons un coefficient de corrélation ? : de -8, vol.9
, 17,0 ; -1,4) en multivariée entre la présence d'une désorganisation des couches rétiniennes internes (DRIL) et l'acuité visuelle, vol.95
, 141,7) en multivariée entre la présence de points hyper-réflectifs (HRD) et l'épaisseur maculaire centrale, vol.5, pp.95-467
, ) en analyse multivariée entre la catégorie OEdème Maculaire Central et l'épaisseur maculaire central. Conclusion : Cette étude confirme l'association des DRIL à la mauvaise récupération visuelle, et des HRD à la diminution du CMT à 6 mois chez les patients traités par Ozurdex® pour un OMD